Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Clinigence Holdings ( (NUTX) ) is now available.
On September 2, 2025, Nutex Health, Inc. appointed Michael L. Reed as the Lead Independent Director of its Board of Directors. Reed, who has been a board member since April 2022, will facilitate communication between independent directors and the company’s management, reinforcing Nutex Health’s commitment to strong corporate governance and compliance with Nasdaq’s requirements. This move highlights the company’s dedication to maintaining robust corporate governance practices.
The most recent analyst rating on (NUTX) stock is a Buy with a $300.00 price target. To see the full list of analyst forecasts on Clinigence Holdings stock, see the NUTX Stock Forecast page.
Spark’s Take on NUTX Stock
According to Spark, TipRanks’ AI Analyst, NUTX is a Neutral.
Nutex Health’s overall stock score reflects strong financial performance and attractive valuation, offset by technical weakness and legal risks. The company’s significant revenue growth and profitability are promising, but increased leverage and legal challenges warrant caution.
To see Spark’s full report on NUTX stock, click here.
More about Clinigence Holdings
Average Trading Volume: 257,560
Technical Sentiment Signal: Sell
Current Market Cap: $449.5M
For detailed information about NUTX stock, go to TipRanks’ Stock Analysis page.